1Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier; and.
2Institute of Functional Genomics (IFG), University of Montpellier, INSERM U1191, Montpellier, France.
J Neurosurg. 2023 Mar 24;139(4):934-943. doi: 10.3171/2023.2.JNS222755. Print 2023 Oct 1.
Surgery for giant diffuse lower-grade gliomas (LGGs) is challenging, and very few data have been reported on this topic in the literature. In this article, the authors investigated surgical, functional, and oncological aspects in patients who underwent awake resection for large LGGs with a volume > 100 cm3.
The authors retrospectively reviewed a consecutive cohort of patients who underwent surgery in an awake condition for an LGG (WHO grade 2 with possible foci of grade 3 transformation) with a volume > 100 cm3.
A total of 108 patients were included, with a mean age of 36.1 ± 8.5 years. The mean presurgical LGG volume was 136.7 ± 34.5 cm3. In all but 2 patients a disconnection resective surgery up to functional boundaries was possible thanks to active patient collaboration during the awake period. At 3 months of follow-up, all but 1 patient had a normal neurological examination, with a mean Karnofsky Performance Status (KPS) score of 89.8 ± 10.36. In all patients with preoperative epilepsy, there was postoperative control or significant reduction of seizure events. Moreover, 85.1% of patients returned to work. The mean extent of resection (EOR) was 88.9% ± 7.0%, with a mean residual tumor volume (RTV) of 16.3 ± 12.0 cm3 (median RTV 15 cm3). Pathological examination revealed 73 grade 2 gliomas (67.6%; 26 oligodendrogliomas and 47 astrocytomas) and 35 gliomas with foci of grade 3 (32.4%; 19 oligodendrogliomas and 16 astrocytomas). During the postoperative period, 93.6% of patients underwent adjuvant chemotherapy with a median interval between surgery and first chemotherapy of 14 months (IQR 2-26 months), and 55% of patients had radiotherapy with a median interval of 38.5 months (IQR 18-59.8 months). At the last follow-up, 69.7% of patients were still alive with a median follow-up of 62 months (IQR 36-99 months). Overall survival (OS) rates at 1, 5, and 10 years were 100% (95% CI 0.99-1), 80% (95% CI 0.72-0.9), and 58% (95% CI 0.45-0.73), respectively. The median OS was 138 months. In multivariable Cox regression analysis, RTV was established as the only independent prognostic factor for survival.
With the application of rigorous surgical methodology based on functional-guided resection, resection of giant LGGs (volume > 100 cm3) can be reproducibly achieved during surgery with patients under awake mapping with both favorable functional results (< 1% permanent neurological worsening) and favorable long-term oncological outcomes (median OS > 11 years, with a more significant benefit when the RTV is < 15 cm3).
对于巨大弥漫性低级别胶质瘤(LGG)的手术极具挑战性,文献中鲜有相关报道。本文作者调查了接受体积> 100 cm³的大型 LGG(WHO 分级 2 级,可能有 3 级转化灶)唤醒切除的患者的手术、功能和肿瘤学方面。
作者回顾性分析了连续接受手术的患者队列,他们因体积> 100 cm³的 LGG(WHO 分级 2 级,可能有 3 级转化灶)而在清醒状态下接受手术。
共纳入 108 例患者,平均年龄 36.1 ± 8.5 岁。术前 LGG 平均体积为 136.7 ± 34.5 cm³。除 2 例患者外,所有患者均能通过在清醒期间积极配合患者达到功能边界进行离断性切除术。术后 3 个月,除 1 例患者外,所有患者均有正常的神经检查,Karnofsky 表现状态(KPS)评分平均为 89.8 ± 10.36。所有术前有癫痫的患者术后均得到控制或明显减少了癫痫发作。此外,85.1%的患者恢复了工作。平均切除范围(EOR)为 88.9%±7.0%,残余肿瘤体积(RTV)平均为 16.3 ± 12.0 cm³(中位 RTV 为 15 cm³)。病理检查显示 73 例 2 级胶质瘤(67.6%;26 例少突胶质细胞瘤和 47 例星形细胞瘤)和 35 例有 3 级转化灶的胶质瘤(32.4%;19 例少突胶质细胞瘤和 16 例星形细胞瘤)。术后期间,93.6%的患者接受了辅助化疗,手术与首次化疗的中位间隔为 14 个月(IQR 2-26 个月),55%的患者接受了放疗,中位间隔为 38.5 个月(IQR 18-59.8 个月)。在最后一次随访时,69.7%的患者仍然存活,中位随访时间为 62 个月(IQR 36-99 个月)。1、5 和 10 年的总生存率(OS)分别为 100%(95%CI 0.99-1)、80%(95%CI 0.72-0.9)和 58%(95%CI 0.45-0.73)。中位 OS 为 138 个月。多变量 Cox 回归分析显示,RTV 是生存的唯一独立预后因素。
通过应用基于功能导向切除的严格手术方法,可以在清醒状态下对体积> 100 cm³的大型 LGG 进行可重复切除,同时具有良好的功能结果(< 1%永久性神经恶化)和良好的长期肿瘤学结果(中位 OS > 11 年,当 RTV < 15 cm³时获益更显著)。